A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis (Q34619709)

3 August 2017

A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis (English)

1 reference

3 August 2017

1 reference

4

Kevin J Anstrom

1 reference

3 August 2017

Idiopathic Pulmonary Fibrosis Clinical Research Network

1

1 reference

3 August 2017

David A Zisman

2

1 reference

3 August 2017

Marvin Schwarz

3

1 reference

3 August 2017

Harold R Collard

5

1 reference

3 August 2017

Kevin R Flaherty

6

1 reference

3 August 2017

Gary W Hunninghake

7

1 reference

3 August 2017

language of work or name

English

0 references

publication date

18 May 2010

1 reference

The New England Journal of Medicine

3 August 2017

1 reference

3 August 2017

363

1 reference

3 August 2017

7

1 reference

3 August 2017

620-628

1 reference

The 6 minute walk in idiopathic pulmonary fibrosis: longitudinal changes and minimum important difference

3 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3587293

The SF-36 and SGRQ: validity and first look at minimum important differences in IPF.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3587293

Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3587293

Sildenafil improves walk distance in idiopathic pulmonary fibrosis

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3587293

Minimally clinically important difference for the UCSD Shortness of Breath Questionnaire, Borg Scale, and Visual Analog Scale

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3587293

Classification of idiopathic interstitial pneumonias: making sense of the alphabet soup

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3587293

Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3587293

Minimal clinically important difference for the UCSD Shortness of Breath Questionnaire.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3587293

Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3587293

Small changes in six-minute walk distance are important in diffuse parenchymal lung disease

26 October 2018

1 reference

12 December 2020

A potential role for sildenafil in the management of pulmonary hypertension in patients with parenchymal lung disease

1 reference

12 December 2020

American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS)

1 reference

12 December 2020

Nitric oxide and endothelin-1 in pulmonary hypertension

1 reference

12 December 2020

Identifiers

DOI

10.1056/NEJMOA1002110

1 reference

3 August 2017

1 reference

3 August 2017

1 reference